1.230SEK-0.81%Mkt Cap: 419.20M SEKP/E: —Last update: 2026-06-01
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against strept…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap419.20M SEK
Enterprise Value303.69M SEK
Revenue (TTM)19.07M SEK
Gross Profit-11.49M SEK
Net Income (TTM)-80.81M SEK
Revenue/Share0.0550 SEK
Last Price1.230 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.51
PEG—
EV/EBITDA-4.13
EV/Revenue15.93
P/S22.16
P/B1.77
EPS (TTM)-0.25
EPS (Forward)-0.82
52W Range
0.572074% of range1.462
52W High1.462 SEK
52W Low0.5720 SEK
Profitability
Gross Margin-57.18%
Oper. Margin-525.61%
EBITDA Margin0.00%
Profit Margin-402.32%
ROE-29.40%
ROA-27.45%
Growth
Revenue Growth-7.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.79M SEK
CapEx (TTM)1.13M SEK
FCF Margin-204.66%
FCF Yield-9.31%
Net Debt-145.27M SEK
Net Debt/EBITDA1.97
Balance Sheet
Debt/Equity0.00
Current Ratio6.46
Quick Ratio6.06
Book Value/Sh0.6990 SEK
Cash/Share0.4020 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)2.100 SEK
Target Range2.100 SEK – 2.100 SEK
# Analysts1
Ownership
Shares Out.340.81M
Float207.47M
Insiders19.34%
Institutions34.37%
Technical
SMA 501.071 (+14.9%)
SMA 2000.9648 (+27.5%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)536.98K
Avg Vol (10d)345.31K
Technical Indicators
RSI (14)56.1
MACD0.0477
MACD Signal0.0564
MACD Hist.-0.0086
BB Upper1.355 SEK
BB Middle1.208 SEK
BB Lower1.061 SEK
BB Width24.29%
ATR (14)0.1056 SEK
Vol Ratio (20d)0.34x